(Total Views: 544)
Posted On: 09/18/2020 9:38:37 PM
Post# of 154011
Lilly on MAB EUA prospects:
Hey shorts, better rush over the The LLY boards and demand new management, quick!
Quote:
“We will be discussing with regulators what the appropriate next steps are,” Skovronsky said. “So, of course, those discussions will include additional clinical trials as well as other options such as EUA. It’s a small dataset for sure, we we have 450 patients in this data set, but the magnitude of the impact on a hard end point years is very exciting and potentially meaningful for patients.”
Topol said that he does not think an EUA would be justified. “I don’t think it would qualify to even consider that,” he said. “That’s encouraging, but that’s different from saying it’s ready for emergency approval.”
Hey shorts, better rush over the The LLY boards and demand new management, quick!
(3)
(0)
